To further enhance the transmission of IL-2 to tumor lesions and improve its therapeutic effect, several groups have combined IL-2/IL-2R mutations with antibody-mediated tumor-targeted delivery strategies (Table 1; Figures 2B, C). The gene discussed is IL2; the disease is neoplasm.